CIGB-300 Anticancer Peptide Differentially Interacts with CK2 Subunits and Regulates Specific Signaling Mediators in a Highly Sensitive Large Cell Lung Carcinoma Cell Model
George Perez(Centro de Ingeniería Genética y Biotecnología), Silvio E. Perea(Centro de Ingeniería Genética y Biotecnología)
Cited by 11
Related Papers
Treatment with an Anti-CK2 Synthetic Peptide Improves Clinical Response in COVID-19 Patients with Pneumonia. A Randomized and Controlled Clinical Trial
|ACS Pharmacology & Translational Science|2020|45
A modified variant of human Interleukin-15 as a novel antigen for active immunotherapy in rheumatoid arthritis
|DOAJ (DOAJ: Directory of Open Access Journals)|2018|0